齐拉西酮治疗首发精神分裂症78例临床研究

Clinical study of ziprasidone in the treatment of 78 patients with first-episode schizophrenia

目的 探讨首发精神分裂症患者接受齐拉西酮治疗的临床疗效.方法 选择2014年1月-2016年6月在浙江省舟山市第二人民医院精神科接受治疗的首发精神分裂症患者156例为研究对象,将其随机均分为2组,对照组采用利培酮进行治疗,观察组选用齐拉西酮进行治疗,对比2组患者的治疗后的临床疗效. 结果 观察组患者治疗的总有效率为97.4%,对照组患者治疗的总有效率为89.7%;观察组患者治疗后的阴性症状评分明显低于对照组,2组对比具有统计学意义（P〈0.05）.结论 齐拉西酮应用于首发精神分裂症的治疗取得了良好的临床疗效,治疗的总有效率较高,有效控制了阴性症状.

Objective To investigate the clinical efficacy of ziprasidone in the treatment of first-episode schizophrenia.Methodsfrom January 2014 to June 2016to receive the treatment of patients with first-episode schizophrenia in 156 cases as the research object in the psychiatric hospital, which were randomly divided into two groups, the control group were given risperidone treatment, the observation group was treated with ziprasidone treatment, compared two groups of clinical curative effect of the treatment of patients after.ResultsThe patients in the observation group the total effective rate was 97.4%, the control group total effective rate was 89.7%;group after treatment in patients with negative symptoms score were significantly lower than the control group, with statistical significance between the two groups （P〈0.05）.ConclusionThe application of ziprasidone in the treatment of first-episode schizophrenia has achieved good clinical efficacy, the total effective rate of treatment is higher, and the negative symptoms are effectively controlled.